Cargando…
Recommendations on Off-Label Drug Use in Pediatric Guidelines
Objective: To systematically analyze the supporting evidence, drug information, and the type of off-label drug use in recommendations on off-label drug use in pediatric guidelines. Methods: A cross-sectional study was performed by systematic search through MEDLINE (via PubMed) and Embase databases t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218488/ https://www.ncbi.nlm.nih.gov/pubmed/35754484 http://dx.doi.org/10.3389/fphar.2022.892574 |
_version_ | 1784731902061576192 |
---|---|
author | Meng, Min Zhou, Qi Lei, Wenjuan Tian, Min Wang, Ping Liu, Yunlan Sun, Yajia Chen, Yaolong Li, Qiu |
author_facet | Meng, Min Zhou, Qi Lei, Wenjuan Tian, Min Wang, Ping Liu, Yunlan Sun, Yajia Chen, Yaolong Li, Qiu |
author_sort | Meng, Min |
collection | PubMed |
description | Objective: To systematically analyze the supporting evidence, drug information, and the type of off-label drug use in recommendations on off-label drug use in pediatric guidelines. Methods: A cross-sectional study was performed by systematic search through MEDLINE (via PubMed) and Embase databases to identify literature published from 1 January 2018, to 31 December 2020. Only pediatric clinical practice guidelines that included recommendations on off-label use of drugs were included. We present descriptive information on the sources of the included guidelines, country, publication year, evidence grading system used, details on the types of off-label drug use, and the types of studies used as references to support the recommendations. Results: A total of 66 pediatric guidelines with 605 recommendations were included. Eighty-seven (14.4%) recommendations did not cite any references; and the remaining 518 recommendations were supported by 2,240 references (mean 4.3 references/recommendation). The most common types of studies cited were pediatric RCTs (n = 314, 14.0%), pediatric case series studies (n = 260, 11.6%), and reviews (n = 255, 11.4%). Twenty-one percent (n = 470) of the references were studies on adults. One hundred and forty (23.1%) recommendations were graded using the Grading of Recommendations, Assessments, Development, and Evaluations (GRADE) system, of which 37 (26.4%) were graded as strong but supported with only C or D level of evidence. The most commonly reported type of information in the recommendations was indication (n = 499, 82.5%). The most commonly addressed type of off-label drug use in the 523 positive recommendations was unapproved population (n = 255, 48.8%). Sixty-nine (11.4%) recommendations explicitly reported the drug use as off-label. Conclusion: Children may be exposed to medical risks due to gaps in reporting and evidence of off-label drug use recommendations in pediatric guidelines. |
format | Online Article Text |
id | pubmed-9218488 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92184882022-06-24 Recommendations on Off-Label Drug Use in Pediatric Guidelines Meng, Min Zhou, Qi Lei, Wenjuan Tian, Min Wang, Ping Liu, Yunlan Sun, Yajia Chen, Yaolong Li, Qiu Front Pharmacol Pharmacology Objective: To systematically analyze the supporting evidence, drug information, and the type of off-label drug use in recommendations on off-label drug use in pediatric guidelines. Methods: A cross-sectional study was performed by systematic search through MEDLINE (via PubMed) and Embase databases to identify literature published from 1 January 2018, to 31 December 2020. Only pediatric clinical practice guidelines that included recommendations on off-label use of drugs were included. We present descriptive information on the sources of the included guidelines, country, publication year, evidence grading system used, details on the types of off-label drug use, and the types of studies used as references to support the recommendations. Results: A total of 66 pediatric guidelines with 605 recommendations were included. Eighty-seven (14.4%) recommendations did not cite any references; and the remaining 518 recommendations were supported by 2,240 references (mean 4.3 references/recommendation). The most common types of studies cited were pediatric RCTs (n = 314, 14.0%), pediatric case series studies (n = 260, 11.6%), and reviews (n = 255, 11.4%). Twenty-one percent (n = 470) of the references were studies on adults. One hundred and forty (23.1%) recommendations were graded using the Grading of Recommendations, Assessments, Development, and Evaluations (GRADE) system, of which 37 (26.4%) were graded as strong but supported with only C or D level of evidence. The most commonly reported type of information in the recommendations was indication (n = 499, 82.5%). The most commonly addressed type of off-label drug use in the 523 positive recommendations was unapproved population (n = 255, 48.8%). Sixty-nine (11.4%) recommendations explicitly reported the drug use as off-label. Conclusion: Children may be exposed to medical risks due to gaps in reporting and evidence of off-label drug use recommendations in pediatric guidelines. Frontiers Media S.A. 2022-06-09 /pmc/articles/PMC9218488/ /pubmed/35754484 http://dx.doi.org/10.3389/fphar.2022.892574 Text en Copyright © 2022 Meng, Zhou, Lei, Tian, Wang, Liu, Sun, Chen and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Meng, Min Zhou, Qi Lei, Wenjuan Tian, Min Wang, Ping Liu, Yunlan Sun, Yajia Chen, Yaolong Li, Qiu Recommendations on Off-Label Drug Use in Pediatric Guidelines |
title | Recommendations on Off-Label Drug Use in Pediatric Guidelines |
title_full | Recommendations on Off-Label Drug Use in Pediatric Guidelines |
title_fullStr | Recommendations on Off-Label Drug Use in Pediatric Guidelines |
title_full_unstemmed | Recommendations on Off-Label Drug Use in Pediatric Guidelines |
title_short | Recommendations on Off-Label Drug Use in Pediatric Guidelines |
title_sort | recommendations on off-label drug use in pediatric guidelines |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218488/ https://www.ncbi.nlm.nih.gov/pubmed/35754484 http://dx.doi.org/10.3389/fphar.2022.892574 |
work_keys_str_mv | AT mengmin recommendationsonofflabeldruguseinpediatricguidelines AT zhouqi recommendationsonofflabeldruguseinpediatricguidelines AT leiwenjuan recommendationsonofflabeldruguseinpediatricguidelines AT tianmin recommendationsonofflabeldruguseinpediatricguidelines AT wangping recommendationsonofflabeldruguseinpediatricguidelines AT liuyunlan recommendationsonofflabeldruguseinpediatricguidelines AT sunyajia recommendationsonofflabeldruguseinpediatricguidelines AT chenyaolong recommendationsonofflabeldruguseinpediatricguidelines AT liqiu recommendationsonofflabeldruguseinpediatricguidelines |